The estimated Net Worth of Fondation Rennes is at least $41.5 Milion dollars as of 13 August 2019. Fondation Rennes owns over 300,000 units of XBiotech Inc stock worth over $18,866,397 and over the last 22 years Fondation sold XBIT stock worth over $22,599,020.
Fondation has made over 28 trades of the XBiotech Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Fondation sold 300,000 units of XBIT stock worth $10,590,000 on 13 August 2019.
The largest trade Fondation's ever made was buying 1,200,000 units of XBiotech Inc stock on 4 June 2019 worth over $9,900,000. On average, Fondation trades about 61,522 units every 160 days since 2002. As of 13 August 2019 Fondation still owns at least 2,915,981 units of XBiotech Inc stock.
You can see the complete history of Fondation Rennes stock trades at the bottom of the page.
Fondation's mailing address filed with the SEC is MEIERHOFSTRASSE 5, , VADUZ, N2, FL-9490.
Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes a W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.
xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..
XBiotech Inc executives and other stock owners filed with the SEC include: